|
|
|
| Effect of Metformin on Reducing the Incidence of Cardiovascular Events and Coronary In-Stent Restenosis after Coronary Intervention in Patients with Coronary Heart Disease |
| FANG Yong, LU Wei, YAN Yu |
| General Hospital of Wanbei Coal and Electricity Group, Anhui Suzhou 234000, China |
|
|
|
|
Abstract Objective: To investigate the effect of metformin on the incidence of in-stent restenosis and cardiovascular events in patients with coronary heart disease who underwent coronary intervention. Methods: From February 2020 to February 2022, 50 patients with coronary heart disease who received coronary intervention in Wanbei Coal and Electricity Group General Hospital were selected retrospectively. According to the postoperative treatment methods, they were divided into two groups: metformin group (metformin plus conventional treatment) and conventional treatment group (25 patients in each group). The general information, laboratory indicators, cardiovascular events and in stent restenosis of the two groups were comparatively analyzed. Results: After treatment, the levels of blood glucose, insulin resistance index, low density lipoprotein, total cholesterol, endolipin, tumor necrosis factor-αand hypersensitive C-reactive protein in 2 groups were lower in the model than before treatment (P<0.05), while the levels of omentin-1 in the model were higher than before treatment (P<0.05). The levels of blood glucose, insulin resistance index, low density lipoprotein, total cholesterol, endolipin, tumor necrosis factor-αand hypersensitive C-reactive protein in metformin group were significantly lower than those in conventional treatment group (P<0.05), while the omentin-1 level model was higher than that in conventional treatment group (P<0.05). The incidence of cardiovascular events in metformin group was 8.00% (2/25) lower than that in conventional treatment group 32.00% (8/25) (χ2=4.500, P<0.05). The incidence of coronary restenosis in metformin group was 12.00% (3/25) significantly lower than that in conventional treatment group (36.00% (9/25) (χ2=3.947, P<0.05). Conclusions: The addition of metformin to conventional treatment in patients with coronary heart disease undergoing coronary intervention can further reduce the levels of blood glucose, blood lipid, inflammatory factors and fat factors, and reduce the incidence of coronary stent restenosis and cardiovascular events.
|
|
|
|
|
|
[1] 沈珈谊,王苏英,李珊,等.浙江省社区中老年人群冠心病患病率调查及危险因素分析[J].临床心血管病杂志,2020,36(9):805-809.
[2] 张善稳,曲小龙,孟璟,等.糖尿病患者冠状动脉介入治疗术后对比剂肾病的危险因素及预后分析[J].重庆医科大学学报,2016,41(4):341-346.
[3] 丁伟芬.盐酸二甲双胍缓释片对冠心病合并糖耐量减低患者PCI术后的效果观察[J].北方药学,2021,18(3):109-110.
[4] 龚玲辉,韩素霞,华靖,等.糖尿病合并冠心病患者冠脉造影术前是否停用二甲双胍对肾功能的影响[J].当代医学,2020,26(31):141-142.
[5] 游赣花,龙向淑,宋方,等.二甲双胍通过lncRNA-MALAT1对人血管平滑肌细胞活力、迁移及凋亡的影响[J].中国病理生理杂志,2019,35(11):1936-1941.
[6] 冯国飞,纪禹同,刘贺萍,等.高龄糖尿病伴肾功损害患者沙格列汀合用二甲双胍致严重低血糖1例[J].中华保健医学杂志,2018,20(4):347-348.
[7] 亓翠玲,亓立勇.赖脯胰岛素25联合吡格列酮预防2型糖尿病患者支架内再狭窄的临床研究[J].实用糖尿病杂志,2014,10(6):31-32.
[8] 林振宇,陈雨.阿司匹林与比索洛尔联合用药对冠心病经皮冠状动脉介入术后患者心脏康复的影响[J].临床和实验医学杂志,2017,16(16):1629-1632. |
|
|
|
2023, Vol. 29 
